Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance - Test2 - elhamkhani - TriplyDB

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

http://www.wikidata.org/entity/Q28166663

about

The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19 Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?Determinants of the interindividual variability in response to antiplatelet drugs Resistance to antiplatelet drugs: current status and future research The variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials.Aspirin and clopidogrel resistance: an emerging clinical entity Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes Response to aspirin and clopidogrel monitored with different platelet function methods Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'Aspirin and clopidogrel resistance: consideration and management Oral antiplatelet therapy and percutaneous coronary intervention Clopidogrel resistance: myth or reality?Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problems Clopidogrel in the treatment of ischaemic heart disease Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?Clopidogrel: an updated and comprehensive review CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.Effect of clopidogrel on the hydroxylation and sulfoxidation of omeprazole: A single dose study in healthy human volunteers.The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty.Clopidogrel "resistance": where are we now?Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.Clinical importance of aspirin and clopidogrel resistance Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.A population-based study of the drug interaction between proton pump inhibitors and clopidogrel Transcriptome analysis of artificial hybrid pufferfish Jiyan-1 and its parental species: implications for pufferfish heterosis.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Cardiovascular pharmacogenomics Effect of gender difference on platelet reactivity.Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond.Antiplatelet resistance and thromboembolic complications in neurointerventional procedures.Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress.In Vitro Assessment of Cytochrome P450 2C19 Potential of Naoxintong Platelet activation in myocardial ischemic syndromes.Antiplatelet drugs: mechanisms and risks of bleeding following cardiac operations Platelet Extracellular Regulated Protein Kinase 5 Is a Redox Switch and Triggers Maladaptive Platelet Responses and Myocardial Infarct Expansion Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.

P2860

Q26801867-644CAC4B-D63C-4C7F-8873-1E30C2F69402 Q27022443-946CA5B5-159C-4200-B7AC-463BA7472D71 Q28187591-AB4E9078-AC0C-4419-BE21-62B623078355 Q28192298-BA7E6D82-BD42-49C9-8B40-170B176EE7A8 Q28192919-F92164D8-1470-4E87-8825-DBD3076CCDD9 Q28194021-A351B894-3D60-4B2F-A53E-53F2E86D27EA Q28199725-3109CA07-A37B-4094-9447-266927697C1D Q28200256-F2C1ADC9-974C-4E9F-B8BF-EE8CB45724B6 Q28200552-523FEECC-B0AD-4D91-81BC-E75AD7EC6F9A Q28200610-403A7CA3-D006-44A3-BBFE-509231738BD7 Q28217724-47B75D07-A6DC-453D-AAAC-F971B7B97298 Q28218055-8780F1EB-F286-47C8-A709-68C89EA0DCE5 Q28218351-419BB7AA-49E6-4B64-9172-EB9066C66FFA Q28218576-7D1D023F-D921-48A3-B0A6-23D8FCFF2CC0 Q28219354-F4A6BDF7-2A35-42C0-8814-C27020DEA1BB Q28219411-E8490B11-CFDE-4C04-970D-CC02CBF8FF5F Q33368192-BBA765D7-8EA1-4546-9755-A97E421F98CC Q33667262-3916A9A8-6F8B-4F3A-B089-B3DB00EDFD1B Q33776115-25004534-CADA-4E48-9FC3-74D0E02B46E2 Q33818356-303E885C-8B88-479E-8FA3-A6560468D0C2 Q33982372-A33E6758-ED7D-4F56-8ECB-E223DA4AD3AE Q34019082-B87BC522-0ABC-4CAC-AD26-8F28AB898E06 Q34150640-A482FC40-0634-4E1A-8767-CF1A8CC23F59 Q34212563-1A579E99-6D09-4C54-8FC2-B1C62118CACC Q34339780-993D15B0-09D8-498F-8C31-89A656E1EE8C Q34390050-ED39E4BE-C4B2-49FB-B4F1-374A21BBC69D Q34568130-6BE97716-0952-443D-9916-5AB707BF8681 Q34603772-A6F116D1-1704-42F3-A3AD-62047B1D5FBA Q34631815-AFC19AEB-AAA8-4481-8F46-C0CE83AAE421 Q34771381-12F5F5F6-35E7-4A62-95DA-A31D61D0391E Q35447163-F23137CC-7A59-42AD-8BFB-858E10790575 Q35473568-9C07B087-A0EA-4275-ADBC-AF83D956141D Q35584682-A628AD5A-D37F-4A38-9657-3D2500FF13A5 Q35750126-ACA1A2E2-68FC-4735-BE69-3AA978531655 Q35792726-553D7B6B-71F9-46D5-BC94-DB60141C4576 Q35796575-A26EB51E-6A95-43C6-AC11-9F74D1579C09 Q35821899-E3635927-52E0-4173-9ACB-8BF117979373 Q35902517-1589640C-DF04-499A-B161-B879B55C3671 Q35940530-6ADED85B-8666-415A-99E2-F4126BD47AC7 Q35951677-5D800D01-F84A-406A-93F6-1E08669E49E9

P2860

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

http://www.wikidata.org/entity/Q28166663

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Contribution of hepatic cytoch ...... enon of clopidogrel resistance

@ast

Contribution of hepatic cytoch ...... enon of clopidogrel resistance

@en

Contribution of hepatic cytoch ...... enon of clopidogrel resistance

@nl

type

label

Contribution of hepatic cytoch ...... enon of clopidogrel resistance

@ast

Contribution of hepatic cytoch ...... enon of clopidogrel resistance

@en

Contribution of hepatic cytoch ...... enon of clopidogrel resistance

@nl

prefLabel

Contribution of hepatic cytoch ...... enon of clopidogrel resistance

@ast

Contribution of hepatic cytoch ...... enon of clopidogrel resistance

@en

Contribution of hepatic cytoch ...... enon of clopidogrel resistance

@nl

P1433

Q28166663-A09B6AC9-6273-48C1-A5EC-6238FE0E74AA

P1476

Q28166663-9398F1C9-FDC2-4972-822D-F12170A72F2A

P2093

Q28166663-0E299305-AC46-424D-9952-866775329D84

Q28166663-1356A9BD-32C0-492B-A5FA-58501EF28E08

Q28166663-42BFE2AA-AEC9-4AF9-ADA1-D94F8A3C83F5

Q28166663-82EAF8F2-160E-4095-B472-9073D61C1E1B

Q28166663-8E135BE7-D6C1-42DA-A845-37A6A1DAD85F

Q28166663-9B9EDABA-0BB3-4801-9AB0-8AF251AA52C4

Q28166663-BE8D195C-D705-4321-BFC1-426D5D052D9B

Q28166663-C75724A7-D8F5-4FD6-9E8B-F7B4DC8AB096

Q28166663-D07BC1B2-90B3-4935-BC50-340B3D4E2780

P304

Q28166663-DA9EC7EC-5EFE-4284-8C9E-A8A7BC9991F8

P31

Q28166663-FD392B3B-7E69-48A2-88D9-42CE0DBF445F

P356

Q28166663-9D9B3D00-DEAB-46A3-902A-9408A4D203CB

P407

Q28166663-771C1833-F527-4B5B-91C2-7B8F5C7929BA

P433

Q28166663-9E3D2962-BE64-4A72-B5C9-400055CBCB6F

P478

Q28166663-8B6F748A-0C83-4461-A4A8-0472844AAFF5

P577

Q28166663-5273CBC6-5946-453C-8697-EF58223C75F9

P698

Q28166663-321DED90-3785-4492-A3B7-C4963199A75B

P921

Q28166663-54EBC021-8AF7-496F-97B1-AE35771DEE3B

P356

01.CIR.0000112378.09325.F9

P1433

P1476

Contribution of hepatic cytoch ...... enon of clopidogrel resistance

@en

P2093

Alan R Tait

http://www.w3.org/2001/XMLSchema#string

Amy S Hopp

http://www.w3.org/2001/XMLSchema#string

Charlene J Neer

http://www.w3.org/2001/XMLSchema#string

David G M Carville

http://www.w3.org/2001/XMLSchema#string

Eric R Bates

http://www.w3.org/2001/XMLSchema#string

Kirk E Guyer

http://www.w3.org/2001/XMLSchema#string

Paul A Gurbel

http://www.w3.org/2001/XMLSchema#string

Paul B Watkins

http://www.w3.org/2001/XMLSchema#string

Wei C Lau

http://www.w3.org/2001/XMLSchema#string

P304

166-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.CIR.0000112378.09325.F9

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P577

2004-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14707025

http://www.w3.org/2001/XMLSchema#string

P921